Literature DB >> 12580371

Genetic predisposition and screening in pediatric cancer.

Samart Pakakasama1, Gail E Tomlinson.   

Abstract

Pediatricians are often the health care providers who first detect the signs and symptoms of childhood cancer. Although pediatric malignancies are rare diseases, early diagnosis is an important factor leading to high cure rates of many types of cancers including retinoblastomara, Wilms' tumor, hepatoblastoma, rhabdomyosarcoma. thyroid carcinoma, and other solid tumors. A number of familial cancer syndromes present with childhood cancers that can be recognized or diagnosed by pediatricians. The genetic origins of several syndromes have been elucidated. Genetic testing is not yet available for all of these inherited cancers. A frequently updated list of genetic tests is available at www.genetests.org. The ordering and interpreting of genetic tests, however, is often best done by trained genetic counselors. The pediatrician will play a vital on-going role in following the at-risk child. In many of syndromes discussed, the cost effectiveness of the tests as well as that of any potential intervention needs further study. The role of the subtle genetic polymorphisms in pediatric tumorigenesis. many more of which will undoubtedly be described in the coming years, has not yet been translated into defined needs for interventions. Perhaps in the future it will be possible to understand the additive effect of multiple genetic polymorphisms and to determine genetic profiles of high cancer risk. Until suitable interventions are established, however, the study of genetic variability and cancer will await practical significance. Undoubtedly other major important cancer genes are yet to be discovered and characterized. An additional challenge is the counseling and management of children and adults who have a strong family history of cancer yet who do not have a recognizable syndrome. The role of the primary pediatrician is to recognize the major cancer genetic syndromes, to make appropriate referrals for genetic counseling and testing when indicated, and to ensure that adequate screening tests are being done.

Entities:  

Mesh:

Year:  2002        PMID: 12580371     DOI: 10.1016/s0031-3955(02)00095-0

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  6 in total

1.  Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma.

Authors:  Mohammed Orloff; Charissa Peterson; Xin He; Shireen Ganapathi; Brandie Heald; Yi-ran Yang; Gurkan Bebek; Todd Romigh; Jee Hoon Song; Wenjing Wu; Stefan David; Yulan Cheng; Stephen J Meltzer; Charis Eng
Journal:  JAMA       Date:  2011-07-27       Impact factor: 56.272

2.  Preserving vision in retinoblastoma through early detection and intervention.

Authors:  Sidnei Epelman
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 3.  Clinical manifestations of genetic instability overlap one another.

Authors:  Károly Méhes; György Kosztolányi
Journal:  Pathol Oncol Res       Date:  2004-03-18       Impact factor: 3.201

4.  PON1 Q192R polymorphism (rs662) is associated with childhood embryonal tumors.

Authors:  Gisele M Vasconcelos; Bruno Aguiar Alves Gonçalves; Rafaela Montalvão-de-Azevedo; Luiz Claúdio Santos Thuler; Flavio Henrique Paraguassu Braga; Maria S Pombo-de-Oliveira; Beatriz de Camargo
Journal:  Mol Biol Rep       Date:  2014-06-28       Impact factor: 2.316

5.  METTL1 gene polymorphisms synergistically confer hepatoblastoma susceptibility.

Authors:  Lili Ge; Jinhong Zhu; Jiabin Liu; Li Li; Jiao Zhang; Jiwen Cheng; Yong Li; Zhonghua Yang; Suhong Li; Jing He; Xianwei Zhang
Journal:  Discov Oncol       Date:  2022-08-20

6.  WDR4 gene polymorphisms increase hepatoblastoma susceptibility in girls.

Authors:  Shaohua He; Jinhong Zhu; Zhixiang Xiao; Jiabin Liu; Jiao Zhang; Yong Li; Zhonghua Yang; Jiwen Cheng; Suhong Li; Li Li; Jing He; Di Xu
Journal:  J Cancer       Date:  2022-09-21       Impact factor: 4.478

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.